HCW Biologics Signs Exclusive Distribution Deal with Akron Biotech for CAR-T Manufacturing Reagent HCW11-006
核心洞察
HCW Biologics entered an exclusive distribution agreement with Akron Biotech (搜索) to commercialize HCW11-006 (搜索), a multi-cytokine fusion molecule used as a reagent in CAR-T cell manufacturing.
HCW11-006 (搜索) combines IL-7, IL-15 (搜索), and IL-21 signals in a single molecule, and preclinical studies showed CAR-T cells made with it had stronger anti-tumor activity and enhanced antiviral potency.
The agreement includes pre-payment commitments for product sales and gives HCW Biologics a commercial route through Akron's network of research institutions and commercial customers.
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company based in Miramar, Florida, has entered into an exclusive distribution agreement with Akron Biotech (搜索) for the commercialization of HCW11-006 (搜索), its first-in-class multi-cytokine fusion molecule designed for use as a reagent in CAR-T cell manufacturing. Announced on September 8, 2026, the agreement positions HCW11-006 as a potential manufacturing reagent to support the production of highly functional human CAR-T cells for treating cancer (搜索), autoimmune disease, and infectious diseases.
Under the terms of the agreement, HCW Biologics will supply both research-grade and current Good Manufacturing Practice (cGMP)-grade HCW11-006 (搜索), while Akron Biotech (搜索) will market and distribute the product through its established network of research institutions and commercial customers. The agreement also includes pre-payment commitments relating to product sales, providing HCW Biologics with a commercial route for HCW11-006 as it seeks to expand the molecule's use in cell therapy manufacturing.
Akron Biotech (搜索) is a leading manufacturer of ancillary materials and a contract development and manufacturing organization serving the cell therapy, gene therapy, and regenerative medicine sectors. The company manufactures and markets cGMP-compliant ancillary materials—including cytokines, media supplements, and plasmid DNA—necessary for bringing regenerative medicine from preclinical stages to commercialization, and operates within a highly specialized global network of biomedical institutions, advanced therapy developers, biopharmaceutical companies, and research organizations.
A Single Molecule Delivering Three Cytokine Signals
HCW11-006 (搜索) is designed to combine the effects of the IL-7, IL-15 (搜索), and IL-21 cytokines within a single fusion molecule, built using the company's proprietary TRBC platform. Dr. Hing C. Wong, founder and chief executive officer of HCW Biologics, described the technology as enabling "a single molecule to deliver synergistic signals from three different immune-stimulatory cytokines."
The molecule is intended to address a key limitation in current CAR-T manufacturing. According to the company, functional persistence of CAR-Ts is limited by conventional and costly manufacturing methods utilizing anti-CD3/CD28 (αCD3/28)/IL-2 stimulation, which generates terminally differentiated and shorter-lived CAR-Ts. By contrast, HCW11-006 (搜索) synergizes the effects of IL-7, IL-15 (搜索), and IL-21 to promote the generation of a CAR-T cell product with a diverse mix of T cell subsets that exhibit a combination of T-memory stem cell (Tscm) self-renewal capacity and enhanced T cell effector function.
As a reagent, HCW11-006 (搜索) stimulates proliferation of CD8+ T cells, particularly those within the Tscm subset. The company reported that HCW11-006 was shown to generate CAR-Ts without requiring αCD3/28/IL-2 activation, producing cells highly enriched in long-lived Tscm that display potent activity across distinct disease experimental models, namely HIV-1 (搜索) and B-cell leukemia (搜索).
Preclinical Evidence and Planned Clinical Studies
In preclinical studies, CAR-T cells manufactured using HCW11-006 (搜索) demonstrated stronger anti-tumor activity and enhanced antiviral potency compared with CAR-T cells produced using conventional methods. The company stated that CAR-Ts manufactured using HCW11-006 were significantly superior compared to CAR-Ts manufactured using standard methods employing αCD3/28/IL-2 reagents for CAR lentiviral transduction and subsequent expansion and persistence of highly active human CAR-Ts.
The supporting preclinical findings were published in Science Advances in March 2026. The study, authored by Cole et al., was titled "IL-7/IL-15 (搜索)/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells."
Dr. Wong noted that an approach employing HCW11-006 (搜索) as a reagent "is highly streamlined and may lower the cost of CAR-T manufacturing compared to existing approaches," adding that "based on experimental models, HCW11-006 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade." Clinical studies are planned to further confirm these preclinical findings.
Commercial Strategy and Outlook
The distribution agreement gives HCW Biologics access to Akron Biotech (搜索)'s established commercial and research network as the company works to broaden adoption of HCW11-006 (搜索) within the growing cell therapy manufacturing market. Dr. Wong explained that research laboratories and companies had approached HCW Biologics directly seeking supply of HCW11-006 to support their cell-based research and development, prompting the decision to partner with a leading supplier to commercialize the reagent.
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics targeting diseases promoted by chronic inflammation, including autoimmune diseases, cancer (搜索), and senescence-associated dysplasia. The company describes itself as a leader in the creation of multi-valent immunotherapeutics with a unique protein-based scaffold without the antibody Fc domain. The Akron Biotech (搜索) agreement adds a commercial component to its activities by positioning HCW11-006 (搜索) as a potential manufacturing reagent for CAR-T therapies, complementing its clinical development and financing strategy focused on business development programs and commercial-ready reagents.